Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Feb
22
Today In Oncology
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo